Skip to main content

Table 2 Means and standard deviations of groups at baseline, 6 weeks and 3 months follow-up

From: A novel brief treatment for methamphetamine use disorders in South Africa: a randomised feasibility trial

Variable

Control (mean [sd])

IDMI (mean [sd])

Substance use (days in 2 weeks)

 Baseline

8.57 (4.29)

9.73 (3.95)

 6 week follow-up

6.43 (4.62)

4.83 (4.86)

 3 month follow-up

6. 90 (4.12)

4.80 (4.97)

Cravings (PENN craving)

 Baseline

22.50 (6.85)

20.37 (7.50)

 6 week follow-up

17.43 (8.35)

15.97 (7.61)

 3 month follow-up

13.13 (10.09)

14.83 (8.35)

Depression (HAM-D)

 Baseline

12.50 (5.25)

12.90 (6.22)

 6 week follow-up

11.23 (5.83)

10.20 (6.50)

 3 month follow-up

8.40 (5.37)

8.53 (6.69)

Anxiety (HAM-A)

 Baseline

20.27 (10.19)

18.70 (10.02)

 6 week follow-up

17.73 (10.08)

13.87 (9.27)

 3 month follow-up

14.63 (9.44)

8.79 (8.00)

Clinical Global Impressions Scale (CGI)

  Baseline

5.13 (0.97)

5.27 (0.91)

 6 week follow-up

4.57 (1.72)

4.03 (1.65)

  3 month follow-up

4.00 (1.89)

3.60 (1.81)

Sheehan disability (family)

 Baseline

8.40 (2.43)

7.77 (2.91)

 6 week follow-up

6.47 (4.02)

5.53 (3.69)

 3 month follow-up

4.50 (3.97)

4.43 (3.31)

Sheehan disability (work)

 Baseline

6.07 (3.85)

7.30 (2.49)

 6 week follow-up

4.70 (4.27)

5.50 (3.42)

 3 month follow-up

4.00 (3.80)

4.50 (3.75)

Sheehan disability (social life)

 Baseline

7.78 (2.27)

7.50 (2.86)

 6 week follow-up

5.53 (4.08)

4.70 (3.96)

 3 month follow-up

3.63 (3.93)

4.27 (3.63)